Wednesday Links

Claim:  it was the Obama administration that paused funding for high-risk (gain of function) studies in 2014. The ban was lifted by none other than Donald Trump in 2017.

Yarvin’s strange argument on populism and Gain-of-Function research

Firing squads are making a comeback.

US patients pay almost three times more than the average price paid in OECD countries for brand drugs, but we pay a third less than other countries for generics.

The case against Medicaid budget cuts. (unimaginative)